2014 ACR/ARHP Annual Meeting

November 14-19, 2014. Boston, MA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 676

Response to Rituximab in Patients with Refractory Systemic Lupus Erythematosus (SLE): Results from a National Multicentre Register
Abstract Number: 897

Resting State Functional Connectivity Differs Between Chronic Fatigue Syndrome Patients and Healthy Controls
Abstract Number: 2857

Restricting Back Pain Is Strongly Associated with Disability in Community-Living Older Persons over the Course of 13 Years
Abstract Number: 1277

Retinal Arteriolar Narrowing and Incidence of Knee Replacement for Osteoarthritis: A Prospective Cohort Study
Abstract Number: 1237

Retroperitoneal Fibrosis and IgG4 Disease: Response to Immunosuppressive Therapy – a Single Centre Retrospective Study
Abstract Number: 281

Retrospective Review of Immobilization Vs. Immediate Resumption of Activity in Patients with Oligoarticular Juvenile Idiopathic Arthritis and Corticosteroid Knee Injections
Abstract Number: 1576

Reversal of Damage in Psoriatic Arthritis
Abstract Number: 187

Revision Arthroplasty in Rheumatoid and Osteoarthritis: Does Methotrexate Decrease Radiographic Lucency in RA Patients?
Abstract Number: 2187

Revisiting RS3PE after Twenty Five Years: A Systematic Review of 250 Cases
Abstract Number: 1352

Rheumatoid Arthritis (RA) Disease Activity Assessment and Population Management Processes Used By Clinician Rheumatologists
Abstract Number: 1889

Rheumatoid Arthritis (RA)-Associated Risk Allele LBH Alters the Function of a Differentially Methylated LBH Enhancer
Abstract Number: 2136

Rheumatoid Arthritis Erosion Detection and Measurement in Longitudinal Datasets Using High-Resolution Peripheral Quantitative Computed Tomography
Abstract Number: 995

Rheumatoid Arthritis Patients Have Alterations in Inherently Autoreactive 9G4+ B-Cell Subpopulations in Peripheral Blood
Abstract Number: 2425

Rheumatoid Arthritis Stable Follow up Visits – 3 Month Versus 6 Month Intervals
Abstract Number: 432

Rheumatoid Arthritis-Associated Interstitial Lung Disease: Risk Factors for Disease Progression

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].